| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1040691762 |
| P356 | DOI | 10.2165/11318100-000000000-00000 |
| P698 | PubMed publication ID | 20067334 |
| P50 | author | Darrell Abernethy | Q18977896 |
| David J. Greenblatt | Q88911712 | ||
| P2093 | author name string | Michael J Hanley | |
| P2860 | cites work | Epidemiologic and economic consequences of the global epidemics of obesity and diabetes | Q22251061 |
| Volume of Distribution as a Function of Time | Q28182420 | ||
| Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects | Q28252893 | ||
| Obesity | Q28275029 | ||
| Bioelectrical impedance analysis--part I: review of principles and methods | Q28283317 | ||
| Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses | Q28285795 | ||
| Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese | Q33303164 | ||
| Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections | Q33347869 | ||
| Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia | Q33375376 | ||
| Human body composition: in vivo methods | Q33881280 | ||
| Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics | Q33937527 | ||
| Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection | Q33981666 | ||
| Cardiac remodeling in obesity. | Q34043589 | ||
| Effects of obesity on pharmacokinetics implications for drug therapy | Q34053786 | ||
| Low-molecular-weight heparins | Q34437479 | ||
| A formula to estimate the approximate surface area if height and weight be known. 1916. | Q34437560 | ||
| Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults | Q34510697 | ||
| Serum alpha 1-acid glycoprotein and the binding of drugs in obesity | Q34514103 | ||
| Body-composition assessment via air-displacement plethysmography in adults and children: a review | Q34543584 | ||
| Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers | Q34565004 | ||
| Obesity and diabetes in the developing world--a growing challenge | Q34603178 | ||
| Nonalcoholic Fatty liver disease and obesity | Q34605022 | ||
| Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects | Q34622156 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 | ||
| Impairment of hepatic microcirculation in fatty liver | Q35639777 | ||
| Obesity in children and young people: a crisis in public health | Q35750710 | ||
| Development of a dosing strategy for enoxaparin in obese patients | Q35825624 | ||
| Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers | Q68538815 | ||
| Phenytoin disposition in obesity. Determination of loading dose | Q70104016 | ||
| Obesity, sex, and acetaminophen disposition | Q70334782 | ||
| Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541 | Q71778665 | ||
| Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen | Q72553329 | ||
| Intravenous ciprofloxacin disposition in obesity | Q72561443 | ||
| The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam | Q72577288 | ||
| Pharmacokinetics of quinine in obesity | Q73321098 | ||
| Obese man treated with drotrecogin alfa (activated) | Q73448897 | ||
| Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing | Q73799751 | ||
| Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children | Q74013116 | ||
| Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study | Q74207807 | ||
| Quantification of doxorubicin in plasma--a comparative study of capillary and venous blood sampling | Q77167426 | ||
| Pharmacokinetic considerations in obesity | Q77752248 | ||
| The impact of obesity and disease on busulfan oral clearance in adults | Q77850474 | ||
| Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient | Q80822060 | ||
| Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis | Q81230074 | ||
| What is the best size descriptor to use for pharmacokinetic studies in the obese? | Q35826324 | ||
| Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin | Q35912780 | ||
| Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers | Q36094001 | ||
| Keeping the young-elderly healthy: is it too late to improve our health through nutrition? | Q36996907 | ||
| Global burden of obesity in 2005 and projections to 2030. | Q37209527 | ||
| Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey | Q37477083 | ||
| Drug disposition in obese humans. An update | Q39738823 | ||
| Is Volume of Distribution at Steady State a Meaningful Kinetic Variable? | Q40160720 | ||
| Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual | Q40179593 | ||
| Pharmacokinetics of drugs in obesity | Q40327645 | ||
| Clinical pharmacokinetics of drugs in obesity. An update | Q40861587 | ||
| A review of in vivo experimental methods to determine the composition of the human body | Q41059260 | ||
| Dual-energy X-ray absorptiometry body composition model: review of physical concepts | Q41315858 | ||
| Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers | Q42686930 | ||
| Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. | Q43613498 | ||
| Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina | Q43901265 | ||
| Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin | Q44119521 | ||
| The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers | Q44139059 | ||
| Body mass index, weight, and oral contraceptive failure risk | Q44309549 | ||
| Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects | Q44393942 | ||
| Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. | Q44464274 | ||
| CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease | Q44527607 | ||
| Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model | Q44548730 | ||
| Glimepiride pharmacokinetics in obese versus non-obese diabetic patients | Q44741629 | ||
| The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients | Q45072586 | ||
| The effects of cisatracurium on morbidly obese women | Q45072590 | ||
| A standard weight descriptor for dose adjustment in the obese patient | Q45165961 | ||
| The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects | Q45188826 | ||
| Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis | Q45258208 | ||
| Linezolid pharmacokinetics in an obese patient. | Q45298818 | ||
| Dosage of enoxaparin among obese and renal impairment patients | Q46454693 | ||
| Skinfold thickness measurements in obese subjects | Q46635546 | ||
| Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study | Q46679444 | ||
| Caution when lean body weight is used as a size descriptor for obese subjects | Q47174277 | ||
| Body weight and risk of oral contraceptive failure | Q47187304 | ||
| The effect of body weight on dalteparin pharmacokinetics. A preliminary study | Q47231213 | ||
| Influence of lean body weight on anticancer drug clearance | Q47246112 | ||
| Pharmacokinetics and Pharmacodynamics of Triazolam After Two Intermittent Doses in Obese and Normal-Weight Men | Q47353103 | ||
| Comment: obese man treated with drotrecogin alfa (activated). | Q48023093 | ||
| Dosing in obesity: a simple solution to a big problem. | Q50660420 | ||
| Quantification of lean bodyweight. | Q50753849 | ||
| Pharmacokinetics of rocuronium bromide in obese female patients. | Q51439537 | ||
| Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. | Q51567247 | ||
| Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. | Q51578283 | ||
| Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. | Q51593328 | ||
| Prolonged accumulation of diazepam in obesity. | Q51852527 | ||
| Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). | Q51860163 | ||
| A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. | Q53826186 | ||
| Simplified calculation of body-surface area. | Q55060911 | ||
| P433 | issue | 2 | |
| P921 | main subject | obesity | Q12174 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 71-87 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Effect of obesity on the pharmacokinetics of drugs in humans | |
| P478 | volume | 49 |
| Q38832009 | A Phase 1 Randomized, Placebo-Controlled Study Assessing the Pharmacokinetics, Safety, and Tolerability of Retosiban in Healthy, Nonpregnant Japanese Subjects |
| Q37518156 | A Phase I study evaluating the effect of age and weight on the pharmacokinetics of an injectable formulation of diclofenac solubilized with hydroxypropyl-β-cyclodextrin |
| Q29248586 | A Review of the Field on Children’s Exposure to Environmental Contaminants: A Risk Assessment Approach |
| Q28082947 | A Review of the Toxicologic Implications of Obesity |
| Q47260853 | A high-fat high-energy diet influences hepatic CYP3A expression and activity in low-birth-weight developing female rats |
| Q36596051 | A physiome interoperability roadmap for personalized drug development. |
| Q28087744 | A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? |
| Q35960873 | Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies |
| Q46028247 | Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin. |
| Q38381805 | Altered drug disposition following bariatric surgery: a research challenge |
| Q37989803 | Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years |
| Q39255176 | Analgesic concentrations of oxycodone--a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy |
| Q35024342 | Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment |
| Q55079673 | Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications. |
| Q37852466 | Antibiotic dosing in critical illness |
| Q42368757 | Antibiotic dosing in obesity: a BIG challenge |
| Q37919151 | Anticoagulating obese patients in the modern era. |
| Q34075909 | Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance |
| Q38420688 | Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. |
| Q84629245 | Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock |
| Q47962744 | Apremilast in psoriasis - a prospective real-world study. |
| Q87491394 | Assessing an enoxaparin dosing protocol in morbidly obese patients |
| Q38846045 | Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients |
| Q28545175 | Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review |
| Q91245071 | Association of statin and its lipophilicity with cardiovascular events in patients receiving chronic dialysis |
| Q51272096 | Attitudes and opinion about adverse drug events of women living in a city of south Italy. |
| Q39523800 | BMI as a Predictor of Spinal Cord Stimulation Success in Chronic Pain Patients |
| Q38000901 | Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision |
| Q46866626 | Body mass index and bioelectrical impedance phase angle as potentially modifiable nutritional markers are independent risk factors for outcome in allogeneic hematopoietic cell transplantation |
| Q38264354 | Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. |
| Q39296233 | Body mass index and response to abatacept in rheumatoid arthritis |
| Q87142111 | Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study |
| Q36245977 | Body mass index influences the response to infliximab in ankylosing spondylitis |
| Q47940583 | Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China |
| Q36802077 | Can paracetamol (acetaminophen) be administered to patients with liver impairment? |
| Q36471339 | Cefoxitin Plasma and Subcutaneous Adipose Tissue Concentration in Patients Undergoing Sleeve Gastrectomy |
| Q38108760 | Challenges in the optimisation of post-operative pain management with opioids in obese patients: a literature review |
| Q49860957 | Challenges to safe and effective pain management in patients with super obesity: case report and literature review. |
| Q38737633 | Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease |
| Q60959855 | Chemoresistance: Intricate Interplay Between Breast Tumor Cells and Adipocytes in the Tumor Microenvironment |
| Q38121735 | Chemotherapy dosing in overweight and obese patients with cancer |
| Q38932206 | Clarification of contraceptive drug pharmacokinetics in obesity |
| Q39004656 | Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus. |
| Q36331619 | Clinical and critical care concerns in severely ill obese patient |
| Q37826300 | Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor |
| Q98178642 | Comparative study of anaesthesia induction in obese dogs using propofol dosages based on lean body weight or total body weight |
| Q40067964 | Comprehensive Guidance for Antibiotic Dosing in Obese Adults |
| Q33418207 | Concentration of amoxicillin in maternal serum, cord blood, amniotic fluid and the placenta after vaginal administration |
| Q33946261 | Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole |
| Q36679868 | Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics |
| Q36802097 | Creatinine-based equations for the adjustment of drug dosage in an obese population. |
| Q38882052 | Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients |
| Q91397080 | Designer Benzodiazepines: A Review of Published Data and Public Health Significance |
| Q35620590 | Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease |
| Q40522952 | Development of a pharmacist-driven protocol for automatic medication dosage adjustments in obese patients |
| Q36644597 | Doripenem Treatment during Continuous Renal Replacement Therapy |
| Q37246076 | Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. |
| Q42430238 | Dosing ethambutol in obese patients. |
| Q89698046 | Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers |
| Q37940887 | Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation |
| Q47154923 | Drug dosing in obese adults |
| Q47288520 | Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. |
| Q48035659 | Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach |
| Q39219941 | Effect of blood protein concentrations on drug-dosing regimes: practical guidance |
| Q38016232 | Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs |
| Q38037349 | Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review |
| Q86202869 | Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients |
| Q58737431 | Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial |
| Q48204147 | Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically Ill patients |
| Q37809138 | Endocrine disrupting chemicals and other substances of concern in food contact materials: An updated review of exposure, effect and risk assessment |
| Q38151813 | Endotherapy for and tailored approaches to treating GERD, and refractory GERD. |
| Q47316479 | Estimation of body weight in hospitalized patients |
| Q90473709 | Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass |
| Q39755697 | Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis |
| Q64105651 | Evaluation of treatment options for methicillin-resistant infections in the obese patient |
| Q36527615 | Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre |
| Q54785515 | Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions. |
| Q38654371 | Fixed Dosing of Monoclonal Antibodies in Oncology |
| Q44311698 | Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration |
| Q53833452 | Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial. |
| Q47649422 | Four-week individual caging of male ICR mice alters body composition without change in body mass. |
| Q36100620 | Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications |
| Q36021921 | Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity |
| Q38675599 | Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height |
| Q33913281 | H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice. |
| Q57119159 | High-Fat Diets Alter the Modulatory Effects of Xenobiotics on Cytochrome P450 Activities |
| Q56832197 | Higher chlorzoxazone clearance in obese children compared with nonobese peers |
| Q50032998 | Hot rods in the ICU : What is the antibiotic mileage of your renal replacement therapy? |
| Q36089185 | How can we improve oral contraceptive success in obese women? |
| Q47192153 | Hypertension in Obesity and the Impact of Weight Loss |
| Q54959708 | IV fosphenytoin in obese patients: Dosing strategies, safety, and efficacy. |
| Q38087384 | Identifying determinants of variability to tailor aspirin therapy |
| Q40330483 | Impact of Norepinephrine Weight-Based Dosing Compared With Non-Weight-Based Dosing in Achieving Time to Goal Mean Arterial Pressure in Obese Patients With Septic Shock |
| Q54231281 | Impact of antenatal corticosteroids in preterm neonates based on maternal body mass index. |
| Q55330048 | Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). |
| Q48312577 | Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia. |
| Q38247400 | Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review |
| Q39033125 | Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study |
| Q35748477 | Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies |
| Q37997025 | Impact of obesity on drug metabolism and elimination in adults and children |
| Q37883897 | Implications of obesity for drug therapy: limitations and challenges |
| Q45741529 | Inadequate therapeutic response to a recommended antituberculosis fixed-dose combination regimen in an overweight patient with Mycobacterium bovis infection |
| Q55417154 | Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study. |
| Q34644461 | Increase in body mass index from normal weight to overweight in a cross-sectional sample of healthy research volunteers |
| Q28543876 | Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review |
| Q37964754 | Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response |
| Q47424028 | Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose. |
| Q35671452 | Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia |
| Q38792564 | Influence of the recipient body mass index on the outcomes after kidney transplantation. |
| Q34792547 | Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients |
| Q24635308 | Innovative clinical trial design for pediatric therapeutics |
| Q59811975 | Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program |
| Q37910895 | Is antiarrhythmic treatment in the elderly different? a review of the specific changes |
| Q42203740 | Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid |
| Q44455948 | Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. |
| Q91793969 | Liver Histological Improvement After Administration of High-Dose Vitamin C in Guinea Pig with Nonalcoholic Steatohepatitis |
| Q37561768 | Low-Dose Urinary Human Chorionic Gonadotropin Is Effective for Oocyte Maturation in In Vitro Fertilization/ Intracytoplasmic Sperm Injection Cycles Independent of Body Mass Index |
| Q55261242 | Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue? |
| Q51554682 | Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. |
| Q26992262 | Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review |
| Q45873262 | Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. |
| Q89584929 | Modern pharmacological treatment of obese patients |
| Q33434316 | Myelosuppression by chemotherapy in obese patients with gynecological cancers |
| Q47223964 | No role for patient body weight on renal function assessment for drug dosing |
| Q35689076 | Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability |
| Q48302820 | Obesity and Altered Aspirin Pharmacology |
| Q48208243 | Obesity and Pediatric Drug Development. |
| Q48224918 | Obesity and allometric scaling of pharmacokinetics |
| Q46260355 | Obesity and its impact on drug therapy: are we ready for this change? |
| Q36017753 | Obesity and lower limb venous disease - The epidemic of phlebesity |
| Q36399698 | Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy |
| Q38310277 | Obesity during pregnancy alters maternal oxidant balance and micronutrient status |
| Q90072667 | Obesity is associated with folate metabolism |
| Q42558993 | Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock |
| Q30407250 | Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary |
| Q64290610 | Oxytocin and Oxytocinase in the Obese and Nonobese Parturients during Induction and Augmentation of Labor |
| Q58117029 | Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance |
| Q37810325 | Patient variation in veterinary medicine - Part II - Influence of physiological variables |
| Q50496500 | Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. |
| Q36247129 | Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. |
| Q88946798 | Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies |
| Q42393159 | Peri-operative management of the obese surgical patient 2015: Association of Anaesthetists of Great Britain and Ireland Society for Obesity and Bariatric Anaesthesia |
| Q40689814 | Perioperative support reduces mortality of obese BALB/c mice after ovariectomy |
| Q38195629 | Pharmacogenomics of episodic migraine: time has come for a step forward. |
| Q37671280 | Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women |
| Q29248398 | Pharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature Review |
| Q42254710 | Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients |
| Q36083619 | Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. |
| Q38614818 | Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery |
| Q38084212 | Pharmacokinetic properties of anti-influenza neuraminidase inhibitors |
| Q41349399 | Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial in |
| Q26771180 | Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections |
| Q40210571 | Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects |
| Q52663906 | Pharmacokinetics of amlodipine besylate at delivery and during lactation. |
| Q36757660 | Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis |
| Q37681127 | Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. |
| Q38062477 | Pharmacologic prevention of venous thromboembolism in obese patients |
| Q58073610 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective |
| Q37790383 | Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science |
| Q48108947 | Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients |
| Q39484436 | Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients |
| Q41139120 | Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients |
| Q48224924 | Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients |
| Q42633482 | Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus |
| Q36924693 | Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers |
| Q92567878 | Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients |
| Q90294280 | Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism |
| Q85791328 | Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model |
| Q35633708 | Prevention of venous thromboembolism in obesity |
| Q45728585 | Prolonged benzodiazepine coma as a complication of morbid obesity. |
| Q50150087 | Relation Between TRCA Complication Rates and Peak ACT Levels Stratified According to the BMI Tertiles |
| Q47194198 | Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging |
| Q35852614 | Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. |
| Q89523218 | Response to Comment on: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study" |
| Q89705642 | Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan |
| Q44899027 | Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. |
| Q50238311 | Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients |
| Q41144399 | Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis |
| Q92357141 | Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity |
| Q55664497 | Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk - a randomised, controlled trial. |
| Q54766719 | Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. |
| Q35004898 | Steady-state plasma pharmacokinetics of oral voriconazole in obese adults |
| Q38106836 | Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature |
| Q41644266 | Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration |
| Q33763123 | The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate |
| Q41980924 | The Effect of Patient Weight and Provider Training and Experience on Dosing of Rocuronium |
| Q36207166 | The Impact of Body Mass Index on the Surgical Outcomes of Patients With Gastric Cancer: A 10-Year, Single-Institution Cohort Study |
| Q91600023 | The Impact of Obesity on the Efficacy of Simvastatin for Lowering Low-Density Lipoprotein Cholesterol in a Veteran Population |
| Q89809795 | The bone mineral density of hip joint was reduced in the initial stage of ankylosing spondylitis? |
| Q36642008 | The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors |
| Q38045375 | The effects of gastric bypass surgery on drug absorption and pharmacokinetics |
| Q37854751 | The effects of obesity on drug pharmacokinetics in humans |
| Q30414240 | The impact of obesity on the immune response to infection |
| Q96116250 | The interference of polypharmacy and the importance of clinical pharmacy advice in the treatment of leprosy: a case-control study |
| Q37709258 | The paroxetine effect on exercise performance depends on the aerobic capacity of exercising individuals |
| Q38491594 | The potential for nutritional components of food items used for enrichment of research animals to act as confounding variables in toxicology studies |
| Q34290110 | Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. |
| Q36111191 | Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology |
| Q42281128 | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. |
| Q39658839 | Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms |
| Q30201915 | Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP. |
| Q26795769 | Vitamin paradox in obesity: Deficiency or excess? |
| Q89336665 | Volume of distribution - Again |
Search more.